scholarly journals Passive Transfer Of Allo-Antibodies Following Rhig Administration Given For Rh-Mismatched Platelets Prophylaxis

2020 ◽  
Vol 154 (Supplement_1) ◽  
pp. S158-S159
Author(s):  
N Sostin ◽  
J Hendrickson ◽  
R Balbuena-Merle ◽  
C Tormey
Keyword(s):  
Older Women ◽  
Retrospective Review ◽  
Case Series ◽  
Passive Transfer ◽  
Human Platelets ◽  
Reproductive Age ◽  
New Haven ◽  
Women Of Reproductive Age ◽  
Antibody Screen ◽  
Haven Hospital

Abstract Introduction/Objective Human platelets (PLTs) do not express any Rh system antigens; however, PLT concentrates can be contaminated with small amounts of red blood cells (RBCs), which may induce alloimmunization when transfused to Rh(D)-negative individuals. RhIG has been utilized to prevent Rh(D) alloantibody development following transfusion of Rh mismatched PLTs. RhIG is manufactured using pooled plasma of healthy Rh(D)-negative donors, with the most common Rh haplotype being ce; treated subjects are exposed to Rh (D)-positive RBCs, with the most common Rh haplotype of donors being DCe. In this report, we detail our experiences with recipients of Rh mismatched apheresis PLTs who were noted to develop anti-D + anti-C post-RhIG administration. Methods Retrospective review was conducted of all Rh mismatched PLTs between December, 2018 and May, 2019 at our facility (Yale-New Haven Hospital, New Haven, CT). Inclusion in the study required: Rh(D)-negative donor receiving one or more Rh(D)-positive apheresis PLTs, Receiving RhIG, >1 antibody screen following RhIG administration demonstrating antibodies other than anti-D Results Our retrospective review identified 8 unique recipients of Rh mismatched apheresis PLTs who acquired anti- C, in addition to the expected anti-D, following administration of RhIG. The product (Rhophylac) was administered in all cases intravenously at a dose of 1500 IU (300 mcg) within 72 hours following Rh mismatched PLTs. In all patients, routine screening following RhIG simultaneously detected anti-D and anti-C 1-3 days after administration of Rh mismatched PLTs/RhIG, the antibody screen remained positive for a range of 27-167 days for both antibodies. Conclusion Based on this case series, which represented entirely men and older women, and coupled with emerging evidence about the extremely low likelihood of D-alloimmunization following Rh mismatched apheresis PLTs,2,3,6 we have changed our practice, limiting immunoprophylaxis for Rh mismatched platelets exclusively to women of reproductive age. The blood bank and apheresis communities should be aware that passive transfer of non-D antibodies is possible when RhIG is dosed and could account for newly-detected non-D alloimmunization events. This phenomenon is another compelling reason to limit RhIG exposure to cases where it is only absolutely clinically necessary.7

THE ASSOCIATION OF THE APOLIPOPROTEIN E4 ALLELE (RS 429358) WITH OVARIAN SEROUS ADENOCARCINOMA

2017 ◽  
Vol 63 (4) ◽  
pp. 627-631
Author(s):  
Tatyana Ivanova ◽  
Nataliya Sychenkova ◽  
Vera Khorokhorina ◽  
Nikolay Ryabchenko ◽  
Sergey Ivanov ◽  
...  
Keyword(s):  
Older Women ◽  
Odds Ratio ◽  
Area Under Curve ◽  
Reproductive Age ◽  
Prognostic Indicators ◽  
Separate Analysis ◽  
Women Of Reproductive Age ◽  
Serous Adenocarcinoma ◽  
Ovarian Serous Adenocarcinoma ◽  
E4 Allele

The distribution of APOE 4 allele (rs 429358, C) was analyzed in healthy women (N=454) and patients with ovarian serous adenocarcinoma (N=114) in order to identify genetic predisposition to the disease. We determined the prognostic indicators of the E4 allele as a marker: odds ratio (OR) and AUC (Area Under Curve) - an area under the ROC curve. It was shown that APOE 4 allele was significantly associated with ovarian serous adenocarcinoma (p = 0,003; 0R=1,94; AUC=0,55). The Е4 genotypes frequency was significantly increased among patients (p = 0.02; 0R=1,8). Separate analysis of the two age subgroups (over 46 years and younger) found that the chance of developing ovarian serous adenocarcinoma was significantly increased for older women (p = 0,006; OR = 2,24, AUC = 0,76). Possible associations of APOE 4 with the ovarian serous adenocarcinoma in women of reproductive age deserve further studying.

Recurrent pleural effusion and pain in the shoulder in women of reproductive age could have a gynecological cause: case series

2019 ◽  
Vol 8 (2) ◽  
Author(s):  
Luka Matak ◽  
Ivan Bačić ◽  
Jakov Mihanović ◽  
Nataša Lisica-Šikić ◽  
Branko Dukić ◽  
...  
Keyword(s):  
Pleural Effusion ◽  
Case Series ◽  
Uterine Cavity ◽  
Reproductive Age ◽  
Women Of Reproductive Age ◽  
Gynecological Disease ◽  
The Right ◽  
Thoracic Endometriosis ◽  
Recurrent Pleural Effusion ◽  
Treatment And Diagnosis

Abstract Background Endometriosis is a benign disorder defined as the presence of endometrial glands and stroma outside of the uterine cavity. It has been estimated that approximately 10% of the women of reproductive age and 30–50% of the women with infertility are affected. Case presentation We report two nulliparous patients with recurrent pleural effusion and pain in the right shoulder highly suspicious for thoracic endometriosis syndrome (TES). Conclusion The objective of this study was to present patients with unusual symptoms related to gynecological disease. The second aim was to show our single institution experience as a second level hospital in terms of treatment and diagnosis of TES and diaphragmatic endometriosis.

scholarly journals A Major Knowledge Gap in Women's Health: The Combined Effect of Antifibrinolytics and Estrogen on Risk of Thromboembolism - a Scoping Review

Blood ◽  
2020 ◽  
Vol 136 (Supplement 1) ◽  
pp. 37-38
Author(s):  
Danielle Meschino ◽  
Daniel Lindsay ◽  
Grace H Tang ◽  
Paula D. James ◽  
Michelle Sholzberg
Keyword(s):  
Research Funding ◽  
Case Reports ◽  
Post Partum ◽  
Case Series ◽  
Advisory Board ◽  
Reproductive Age ◽  
Women Of Reproductive Age ◽  
Antifibrinolytic Agents ◽  
Scientific Advisory Board ◽  
Scientific Advisory

Background:Up to 30% of women of reproductive age will seek medical attention for heavy menstrual bleeding (HMB), which negatively affects health-related quality of life. Both estrogen-containing oral contraceptives and antifibrinolytic agents are essential first-line treatments for HMB. Anecdotally, these agents appear synergistically effective when used in combination. Despite the strong evidence for the independent efficacy and safety of these agents for HMB as well as the use of antifibrinolytics in other high-estrogen states such as the post-partum state, prescribers are frequently uncomfortable prescribing them in combination due to the theoretical increased risk of thrombosis. Objective:To systematically evaluate the literature that explores the combined effect of pharmacologic or high physiologic estrogen and antifibrinolytic agents on risk of thromboembolism in women of reproductive age when used for heavy menstrual or post-partum bleeding. Methods:A literature search was performed on Medline, EMBASE, CINAHL, and Scopus from inception to July 2020. References of included articles were screened and a grey literature search was conducted to identify additional sources. Studies written in English that explored the risk of thromboembolism in women of reproductive age prescribed antifibrinolytic agents alongside estrogen-containing contraceptives or with a physiologic high-estrogen state were included. A thromboembolic event was defined as formation of a blood clot/thrombus in any arterial or venous structure with or without travel to a site distal to its point of origin, confirmed by appropriate diagnostic imaging/testing (including but not limited to deep vein thrombosis, superficial vein thrombosis, pulmonary embolism, ischemic stroke, myocardial infarction, mesenteric ischemia, ischemic colitis, kidney/spleen/liver infarct, or critical limb ischemia). Screening and data abstraction were performed by two independent reviewers (DM, DL) and conflicts were adjudicated by a third reviewer (MS). Results:A total of 2389 title and abstracts were identified from the literature. Of those, a total of 33 studies with 27933 participants were extracted for full text review. Of these studies, 31 investigatedantifibrinolytic use for post-partum bleeding: 22 randomized controlled trials (RCT), 3 retrospective cohort studies, 1 combined prospective-retrospective cohort study, 2 case series, and 3 case reports. Almost all (29/31) of these studies found no increased rate/risk of thromboembolism. However, only 4 of these studies were powered to make this assessment, all of which were RCTs. The 2 studies that described thromboembolism with antifibrinolytic use in the postpartum period were a case report and case series (N=18), respectively. We found only 2 case reports published describing thromboembolism withconcomitant estrogen-containing contraceptives and antifibrinolytic use, both of which reported thromboembolism in women using both agents for less than 3 months. Conclusions:We found no clear evidence that intermittent use of antifibrinolytics in either high physiologic or pharmacologic estrogenic states results in higher rates of thromboembolism. Prospective studies are warranted, particularly in the area of combined estrogen-containing contraceptive and antifibrinolytic use, to provide an accurate assessment of risk and properly inform prescribing practices. Disclosures James: Shire/Takeda:Research Funding;Bayer:Research Funding;CSL Behring:Research Funding.Sholzberg:Amgen:Honoraria, Other: Scientific Advisory Board, Research Funding;Octapharma:Honoraria, Other: Scientific Advisory Board, Research Funding;Takeda:Honoraria, Other: Scientific Advisory Board, Research Funding;Novartis:Honoraria, Other: Scientific Advisory Board;NovoNordisk:Honoraria, Other: Scientific Advisory Board.

scholarly journals A 3-year retrospective review of mortality in women of reproductive age in a tertiary health facility in Port Harcourt, Nigeria

2017 ◽  
Vol Volume 9 ◽  
pp. 769-775 ◽  
Author(s):  
Ngozi Orazulike ◽  
Justina Alegbeleye ◽  
Christopher Obiorah ◽  
Tamunomie Nyengidiki ◽  
Samuel Uzoigwe
Keyword(s):  
Health Facility ◽  
Retrospective Review ◽  
Reproductive Age ◽  
Women Of Reproductive Age ◽  
Port Harcourt

scholarly journals Do Older Women of Reproductive Age Have Better Diet Quality than Younger Women of Reproductive Age?

Nutrients ◽  
2021 ◽  
Vol 13 (11) ◽  
pp. 3830
Author(s):  
Nahal Habibi ◽  
Katherine M. Livingstone ◽  
Suzanne Edwards ◽  
Jessica A. Grieger
Keyword(s):  
Older Women ◽  
Diet Quality ◽  
Food Group ◽  
Dietary Guidelines ◽  
Reproductive Age ◽  
Dietary Intakes ◽  
Dietary Recommendations ◽  
Women Of Reproductive Age ◽  
Younger Women ◽  
Reproductive Aged Women

There is increasing recognition of the importance of nutrition for reproductive health, but little is known regarding the diet quality of younger vs. older reproductive aged women, and how their intakes relate to dietary recommendations. The purpose of the study was to examine the diets of younger (19–35 years old) compared to older (35–50 years old) reproductive aged women, and how they align with dietary recommendations. Women aged 19–50 years from the 2011–13 Australian National Nutrition and Physical Activity Survey were included (n = 2323). Dietary intakes were assessed by a single 24-h dietary recall and were compared to (i) Australian Dietary Guidelines; (ii) Acceptable Macronutrient Distribution for protein, carbohydrates, and fat; and (iii) Dietary Guideline Index (DGI). Regression analyses comparing younger and older women against recommendations were undertaken, with confounders determined a priori. There was no difference between older and younger women in meeting food group recommendations, with 26% of all women meeting recommendations for fruit, and meat and alternatives, and <20% meeting recommendations for vegetables and alternatives, grains, and dairy. Although there was no difference between older and younger women in total DGI score (mean (SE) 75.6 (1.7) vs. 74.5 (2.5), p > 0.05), older women had higher component scores in limiting saturated fat, consuming low-fat milk, and limiting adding salt during cooking. Continued health promotion for women of reproductive age should be a key priority to improve their own health and that of future generations.

scholarly journals Factors associated with modern contraceptive use: a comparative analysis between younger and older women in Umlazi Township, KwaZulu-Natal, South Africa

2021 ◽  
Vol 17 ◽  
pp. 174550652110606
Author(s):  
Mbuzeleni Hlongwa ◽  
Chester Kalinda ◽  
Karl Peltzer ◽  
Khumbulani Hlongwana
Keyword(s):  
Older Women ◽  
Contraceptive Use ◽  
Unplanned Pregnancy ◽  
Reproductive Age ◽  
Modern Contraceptive ◽  
Women Of Reproductive Age ◽  
Level Of Education ◽  
Factors Associated ◽  
Kwazulu Natal ◽  
Modern Contraceptive Use

Introduction: Unplanned pregnancy continues to be a global reproductive and public health concern among women. This study aimed to investigate whether factors associated with modern contraceptive use differ by age-group among young and older women of reproductive age. Methods: This was a cross-sectional study conducted among 433 women of reproductive age, with the median age of 25 years (interquartile range: 21–28), and aged between 18 and 49. Data were collected from 10 public health care clinics in Umlazi Township, KwaZulu-Natal, using a structured questionnaire. Data were coded, entered into Epi Data Manager and exported to Stata for analysis. A Pearson’s chi-square test and logistic regression models were employed to assess the level of the association between the predictor and outcome variables, and the p-value of 0.05 or lower was considered statistically significant. Results: Most women in the sample (n = 351, 81%) had obtained a secondary level of education, while 53% (n = 230) were unemployed and 89% (n = 387) were single. We found that women with secondary level of education (AOR: 2.89, 95% CI: 0.99–5.38) or a tertiary level of education (AOR 3.80, 95% CI: 1.07–3.53) were more likely to use contraceptive methods compared to women with lower education. Women who experienced unplanned pregnancy (AOR 0.51, 95% CI: 0.22–3.79) were more likely to use contraceptives. Women aged 25–49 years who experienced pregnancy, whether planned (AOR 3.87, 95% CI: 1.08–3.89) or unplanned (AOR 3.60, 95% CI: 2.15–4.19), were more likely to use a contraceptive method. Results showed that the level of education (p = 0.942) and whether one experienced unplanned pregnancy (p = 0.913) were not significant predictors of contraceptive use among women aged 18–24 years. Conclusion: Concerted educational efforts to addressing existing barriers deterring women from accessing contraception among young women are necessary. Different groups of women should be targeted with family planning interventions specific to their needs.

scholarly journals Association Between Biomarkers of Ovarian Reserve and Infertility Among Older Women of Reproductive Age

JAMA ◽  
2017 ◽  
Vol 318 (14) ◽  
pp. 1367 ◽  
Author(s):  
Anne Z. Steiner ◽  
David Pritchard ◽  
Frank Z. Stanczyk ◽  
James S. Kesner ◽  
Juliana W. Meadows ◽  
...  
Keyword(s):  
Older Women ◽  
Ovarian Reserve ◽  
Reproductive Age ◽  
Women Of Reproductive Age

Evaluation of concomitant gynecological pathology in group of patients of reproductive age with tumors and tumor formations

2020 ◽  
pp. 10-14
Author(s):  
N. V. Spiridonova ◽  
A. A. Demura ◽  
V. Yu. Schukin
Keyword(s):  
Diagnostic Errors ◽  
Ovarian Tumors ◽  
Reproductive Age ◽  
Women Of Reproductive Age ◽  
Predisposing Factor ◽  
Ovarian Tumours ◽  
Preoperative Diagnostic ◽  
Neoplastic Process ◽  
History Of ◽  
The Moment

According to modern literature, the frequency of preoperative diagnostic errors for tumour-like formations is 30.9–45.6%, for malignant ovarian tumors is 25.0–51.0%. The complexity of this situation is asymptomatic tumor in the ovaries and failure to identify a neoplastic process, which is especially important for young women, as well as ease the transition of tumors from one category to another (evolution of the tumor) and the source of the aggressive behavior of the tumor. The purpose of our study was to evaluate the history of concomitant gynecological pathology in a group of patients of reproductive age with ovarian tumors and tumoroid formations, as a predisposing factor for the development of neoplastic process in the ovaries. In our work, we collected and processed complaints and data of obstetric and gynecological anamnesis of 168 patients of reproductive age (18–40 years), operated on the basis of the Department of oncogynecology for tumors and ovarian tumours in the Samara Regional Clinical Oncology Dispensary from 2012 to 2015. We can conclude that since the prognosis of neoplastic process in the ovaries is generally good with timely detection and this disease occurs mainly in women of reproductive age, doctors need to know that when assessing the parity and the presence of gynecological pathology at the moment or in anamnesis, it is not possible to identify alarming risk factors for the development of cancer in the ovaries.

Sign in / Sign up

Export Citation Format

Share Document